Äڷγª¹ÙÀÌ·¯½º-CoV-2 ¹ÙÀÌ·¯½º¿¡ ÀÇÇÑ Áúº´ÀÇ ±Þ¼ÓÇÑ È®»êÀº ÀÌÀü¿¡ È¿´ÉÀÌ ÀÔÁõµÇÁö ¾ÊÀº º¹¼öÀÇ Ä¡·áÁ¦¸¦ »ç¿ëÇÏ°Ô µÇ¾ú´Ù. º» ¿¬±¸ÀÇ ¸ñÀûÀº COVID-19·Î ÀÔ¿øÇÑ È¯ÀÚµéÀÇ ¾ÆÁöÆ®·Î¸¶À̽Š»ç¿ë°ú ÆóÁúȯÀÇ ÁøÈ ¶Ç´Â Åð¿ø ½Ã°£ »çÀÌ¿¡ ¿¬°ü¼ºÀÌ ÀÖ´ÂÁö ºÐ¼®ÇÏ´Â °ÍÀ̾ú´Ù.
Á¦ 1Æí Äڷγª¹ÙÀÌ·¯½º Á¤ÀÇ
1. Äڷγª¹ÙÀÌ·¯½º°¨¿°Áõ-19(Covid-19) Á¤º¸ 7
2. Äڷγª¹ÙÀÌ·¯½º ºÐ·ù ¹× Ư¼º 9
3. Äڷγª¹ÙÀÌ·¯½º ÀüÀÚÇö¹Ì°æ ÇüÅ 11
4. Äڷγª¹ÙÀÌ·¯½º ±¸Á¶ (Covid-19 Organization) 13
5. Äڷγª19: ȯ°æ¿¡ Áö¼ÓÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥±î? 19
6. Ä¡·á¹ý(Therapeutical Method) 22
Á¦ 2Æí ¿¬±¸³í¹®
Observational study of azithromycin in hospitalized patients with COVID-19
1. Introduction 24
2. Methods 25
3. Results 27
4. Discussion 28
5. Acknowledgments 33
6. References 33